inties associated with regulation of the company's tests by the FDA and other regulatory organizations; the company's ability to compete against third parties; the company's ability to develop and commercialize new tests; unanticipated costs or delays in research and development efforts; the success of the company's next generation sequencing technology; the company's ability to successfully commercialize its tests outside of the United States; the ability to obtain capital when needed; the company's history of operating losses; the results of clinical studies; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2013. These forward- looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
GENOMIC HEALTH, INC.Condensed Consolidated Statements of Income(In thousands, except per share amounts)(Unaudited)Three Months EndedSix Months EndedJune 30,June 30,2013201220132012REVENUES:Product revenues$
115,088Contract revenues-4463851,010Total revenues63,69157,631126,785116,098OPERATING EXPENSES (1):Cost of product revenues10,7579,01320,50318,340Research and development13,80011,57927,46323,508Selling and marketing28,13523,76555,57448,131General and administrative13,91011,43627,04523,411Total operating expenses66,60255,793130,585113,390Income (loss) from operations(2,911)1,838(3,800)2,708Interest income5774122149OtPage: 1 2 3 4 5 6 7 8 Related medicine technology :1
. AbGenomics International has raised $9.6 million for advancing its psoriasis phase-II trials in US2
. Clontech Laboratories, Inc. Partners With Rubicon Genomics To Increase Speed And Efficiency Of Sample Preparation For RNA Sequencing3
. Genomic Health Announces Results of Ten Studies in Breast, Prostate and Colon Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting4
. Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference5
. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals6
. Rosetta Genomics Receives Full Settlement Payment from Sanra Laboratories7
. Genomic Health Announces First Quarter 2013 Financial Results and Business Progress8
. Family Tree DNAs Genomics Research Center Facilitates Discovery of Extremely Ancient Root to the Human Y Chromosome Phylogenetic Tree9
. H3 Biomedicine and BGI Announce Collaboration to Develop and Share Crucial Cancer Genomic Sequencing Data10
. Rosetta Genomics Receives Two Key U.S. Patent Allowances11
. Genomic Health Announces Year-End 2012 Financial Results, Provides 2013 Financial Outlook